Press Releases

CareDx Files Second Lawsuit Against Natera BRISBANE, Calif. , April 10, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on creating diagnostic solutions for organ transplant patients, has filed a second lawsuit against Natera, Inc.

CareDx commitment to transplant innovation highlighted through seven podium and poster presentations BRISBANE, Calif. , April 03, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically

CareDx protects innovation in transplantation by enforcing patent protection BRISBANE, Calif. , March 26, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated,

Cedars Sinai enrolls first patient in a study that uses AlloSure to characterize patient response to therapy BRISBANE, Calif. , March 13, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically

Alongside AlloSure Heart Validation, CareDx advances SHORE enrollment    BRISBANE, Calif. , March 11, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value

AlloSure launch momentum drives 88% fourth quarter revenue growth BRISBANE, Calif. , March 06, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic

CMS initiative “Patients over Paperwork” aims to increase organ availability BRISBANE, Calif. , March 05, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value

BRISBANE, Calif. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag ,

New data highlights the value of AlloSure to detect rejection in one of the most complex transplanted organs BRISBANE, Calif. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically

AlloSure highlighted at Cutting Edge in Transplantation conference in multiple sessions BRISBANE, Calif. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated,